I agree that this site is using cookies. You can find further informations here.
X
Soderlund, Stina
57  results:
OpenAccess-fulltext X
Search for persons X
?
1

Characterization of Bone Marrow Niche in Chronic Myeloid Le..:

Dolinska, Monika ; Cai, Huan ; Mansson, Alma...
Blood, 0006-4971, 2023, 142:1, s. 73-89.  , 2023
Link: http://urn.kb.se/resolve..
 
?
2

IFN-α with dasatinib broadens the immune repertoire in pati..:

Huuhtanen, Jani ; Ilander, Mette ; Yadav, Bhagwan...
JOURNAL OF CLINICAL INVESTIGATION.  , 2022
Link: https://aaltodoc.aalto.f..
 
?
3

IFN-α with dasatinib broadens the immune repertoire in pati..:

Huuhtanen, Jani ; Ilander, Mette ; Yadav, Bhagwan...
urn:issn:0021-9738.  , 2022
Link: https://hdl.handle.net/1..
 
?
4

IFN-a with dasatinib broadens the immune repertoire in pati..:

Huuhtanen, Jani ; Ilander, Mette ; Yadav, Bhagwan...
Journal of Clinical Investigation, 0021-9738, 2022, 132:17,.  , 2022
Link: http://urn.kb.se/resolve..
 
?
5

IFN-α with dasatinib broadens the immune repertoire in pati..:

Huuhtanen, Jani ; Ilander, Mette ; Yadav, Bhagwan...
10.1172/JCI152585.  , 2022
Link: http://hdl.handle.net/10..
 
?
6

Molecular status 36 months after TKI discontinuation in CML..:

Richter, Johan ; Lubking, Anna ; Soderlund, Stina...
10.1038/s41375-021-01173-w.  , 2022
Link: http://hdl.handle.net/10..
 
?
7

Long-term tolerability and efficacy after initial PegIFN-al..:

Flygt, Hjalmar ; Söderlund, Stina ; Stentoft, Jesper...
10.1111/ejh.13699.  , 2022
Link: http://hdl.handle.net/10..
 
?
8

IFN-alfa with dasatinib broadens the immune repertoire in p..:

Huuhtanen, Jani ; Ilander, Mette ; Yadav, Bhagwan...
Journal of Clinical Investigation, 0021-9738, 2022, 132:17,.  , 2022
Link: http://urn.kb.se/resolve..
 
?
9

IFN-α with dasatinib broadens the immune repertoire in pati..:

Huuhtanen, Jani ; Ilander, Mette ; Yadav, Bhagwan...
Journal of Clinical Investigation. 2022, 132 (17), ..  , 2022
Link: https://hdl.handle.net/1..
 
?
10

Successful tyrosine kinase inhibitor discontinuation outsid..:

Flygt, Hjalmar ; Sandin, Fredrik ; Dahlen, Torsten...
British Journal of Haematology, 0007-1048, 2021, 193:5, s. 915-921.  , 2021
Link: http://urn.kb.se/resolve..
 
?
11

Long-term tolerability and efficacy after initial PegIFN-α ..:

Flygt, Hjalmar ; Söderlund, Stina ; Stentoft, Jesper...
https://pure.au.dk/portal/da/publications/longterm-tolerability-and-efficacy-after-initial-pegifn-addition-to-dasatinib-in-cmlcp(12ec8ae0-525f-42a6-8df6-bcd95252bcb7).html.  , 2021
Link: https://pure.au.dk/porta..
 
?
12

Successful tyrosine kinase inhibitor discontinuation outsid..:

Flygt, Hjalmar ; Sandin, Fredrik ; Dahlén, Torsten...
British Journal of Haematology, 0007-1048, 2021, 193:5, s. 915-921.  , 2021
Link: http://urn.kb.se/resolve..
 
?
13

Molecular status 36 months after TKI discontinuation in CML..:

Richter, Johan ; Lubking, Anna ; Soderlund, Stina...
Leukemia, 0887-6924, 2021, 35, s. 2416-2418.  , 2021
Link: http://urn.kb.se/resolve..
 
?
14

Long-term tolerability and efficacy after initial PegIFN-α ..:

Flygt, Hjalmar ; Söderlund, Stina ; Stentoft, Jesper...
European Journal of Haematology, 0902-4441, 2021, 107:6, s. 617-623.  , 2021
Link: http://urn.kb.se/resolve..
 
?
15

Molecular status 36 months after TKI discontinuation in CML..:

Richter, Johan ; Lübking, Anna ; Söderlund, Stina...
Leukemia. 2021, 35 2416-2418..  , 2021
Link: https://hdl.handle.net/1..
 
1-15